These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33028759)

  • 1. Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data.
    Shimada K; Hamada S; Sawano M; Yamamoto H; Yoshie S; Iijima K; Miyata H
    Tohoku J Exp Med; 2020 Oct; 252(2):143-152. PubMed ID: 33028759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of 12-Month Post-Myocardial Infarction Medication Use According to Revascularisation Strategy: Analysis of 15,339 Admissions in Victoria, Australia.
    Livori AC; Ademi Z; Ilomäki J; Nelson AJ; Bell JS; Morton JI
    Heart Lung Circ; 2024 Oct; 33(10):1439-1449. PubMed ID: 38964944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention.
    Lapa ME; Swabe GM; Rollman BL; Muldoon MF; Thurston RC; Magnani JW
    JAMA Netw Open; 2022 Dec; 5(12):e2246317. PubMed ID: 36508214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
    Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Valle JA; O'Donnell CI; Armstrong EJ; Bradley SM; Maddox TM; Ho PM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27184399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Rates of Guideline-Directed Medications Are Associated With In-Hospital Mortality Among Japanese Patients With Acute Myocardial Infarction: A Report From JROAD - DPC Study.
    Nakao K; Yasuda S; Nishimura K; Noguchi T; Nakai M; Miyamoto Y; Sumita Y; Shishido T; Anzai T; Ito H; Tsutsui H; Saito Y; Komuro I; Ogawa H
    J Am Heart Assoc; 2019 Apr; 8(7):e009692. PubMed ID: 30909774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
    Bruggmann C; Iglesias JF; Gex-Fabry M; Fesselet R; Vogt P; Sadeghipour F; Voirol P
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):105-115. PubMed ID: 31300969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
    Chrischilles EA; Schneider KM; Schroeder MC; Letuchy E; Wallace RB; Robinson JG; Brooks JM
    J Am Geriatr Soc; 2016 Mar; 64(3):526-35. PubMed ID: 26928940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
    Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D
    Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M; Alagna M; Lallo A; Gilmore KJ; Francesconi P; Profili F; Scondotto S; Fantaci G; Trifirò G; Isgrò V; Davoli M; Fusco D
    BMC Cardiovasc Disord; 2021 Apr; 21(1):180. PubMed ID: 33853534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Figtree GA; Vernon ST; Hadziosmanovic N; Sundström J; Alfredsson J; Arnott C; Delatour V; Leósdóttir M; Hagström E
    Lancet; 2021 Mar; 397(10279):1085-1094. PubMed ID: 33711294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of Insufficient Optimal Medical Therapy after Acute Myocardial Infarction.
    Haraguchi Y; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
    Intern Med; 2020 Jun; 59(12):1489-1495. PubMed ID: 32188806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Abdu FA; Liu L; Mohammed AQ; Xu B; Yin G; Xu S; Xu Y; Che W
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):678-683. PubMed ID: 33284169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
    Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.